Cyclerion Therapeutics, Inc.
CYCN
$2.76
$0.2158.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.17M | 2.08M | 2.00M | 194.00K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.17M | 2.08M | 2.00M | 194.00K | -- |
| Cost of Revenue | 56.00K | 105.00K | 105.00K | 105.00K | 105.00K |
| Gross Profit | 2.12M | 1.98M | 1.90M | 89.00K | -105.00K |
| SG&A Expenses | 5.70M | 5.27M | 5.34M | 6.07M | 6.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.93M | 5.55M | 5.63M | 6.12M | 7.51M |
| Operating Income | -3.76M | -3.47M | -3.63M | -5.93M | -7.51M |
| Income Before Tax | -1.95M | -2.94M | -3.06M | -5.28M | -10.47M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.95 | -2.94 | -3.06 | -5.28 | -10.47 |
| Earnings from Discontinued Operations | -- | -- | -- | 0.00 | 13.47M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.95M | -2.94M | -3.06M | -5.28M | 3.01M |
| EBIT | -3.76M | -3.47M | -3.63M | -5.93M | -7.51M |
| EBITDA | -- | -- | -- | -1.78M | -4.47M |
| EPS Basic | -0.74 | -1.16 | -1.22 | -2.13 | 1.26 |
| Normalized Basic EPS | -0.73 | -0.73 | -0.76 | -1.31 | -1.80 |
| EPS Diluted | -0.75 | -1.17 | -1.23 | -2.13 | 1.26 |
| Normalized Diluted EPS | -0.73 | -0.73 | -0.76 | -1.31 | -1.80 |
| Average Basic Shares Outstanding | 10.70M | 10.13M | 10.07M | 9.87M | 9.78M |
| Average Diluted Shares Outstanding | 10.70M | 10.13M | 10.07M | 9.87M | 9.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |